India Seeks Predictable Pharma Rules in Brazil to Boost Exports

India has formally requested that Brazil establish a more predictable regulatory environment and facilitate enhanced market access for Indian pharmaceutical products. This crucial discussion took place during the eighth meeting of the India-Brazil Trade Monitoring Mechanism (TMM) held in Brasilia.

Commerce Secretary Rajesh Agarwal attended the meeting, where India underscored its capacity to provide affordable, high-quality medicines. This initiative aims to bolster efforts towards more accessible healthcare within Brazil.

Advancing Broader Trade Agreements

Beyond pharmaceutical specifics, both nations concurred on the prompt finalization of terms of reference (ToR) for commencing negotiations to expand the existing trade pact. This expansion targets the current agreement between New Delhi and the South American bloc Mercosur.

Mercosur itself is a significant regional trade bloc, encompassing Brazil, Argentina, Uruguay, and Paraguay. The India-Mercosur Preferential Trade Agreement (PTA) initially became effective on June 1, 2009, offering limited tariff concessions on 450 products.

The current discussions aim to broaden the scope of this PTA into a comprehensive, full-fledged agreement. Such an expansion represents a considerable opportunity for modernization and deeper economic integration between India and the Mercosur member states.

Key Bilateral Trade Figures

• Bilateral trade between India and the Mercosur bloc reached $20.84 billion in 2025.
• India’s bilateral trade with Brazil stood at $15.07 billion in 2025-26.
• Both India and Brazil have jointly set an ambitious target to increase bilateral trade to $30 billion by 2030.

These ongoing discussions highlight a strategic push by India to strengthen its trade relationships and secure more favorable conditions for its key export sectors. The focus on regulatory predictability aims to unlock further growth potential in the Brazilian market.